Back to results
US 2026/0061078 A1Published application
Adenoviral-Based In Situ Delivery of Bispecific T Cell Engagers
AssigneeUniversitäT ZüRich
InventorsJonas KOLIBIUS, Patrick Christian FREITAG, Andreas PLÜCKTHUN, Ronja WIEBOLDT, Heinz LÄUBLI
Life of this patent
Estimating the term…
Abstract
Disclosed herein are recombinant non-oncolytic viruses, for example adenoviruses, that encode bispecific T cell engagers (BiTE's). These BiTE's can be expressed at any desired site of the human body. The non-oncolytic viruses are able to direct expression of the BiTE's in situ, i.e. directly at the site at which the BiTE's exert their action. The non-oncolytic viruses are useful in the treatment of diseases such, as cancer.
Claims17
1:
- A recombinant non-oncolytic virus comprising a bispecific T cell engager and a recombinant adapter molecule, wherein said recombinant adapter molecule comprises
- a) a designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface,
- b) a designed ankyrin repeat domain which binds to the knob of the adenovirus, and
- c) a trimerization domain.
1 more element
2:
- The non-oncolytic virus according to claim 1, wherein said bispecific T cell engager comprises
- a) a first binding domain comprising a VH domain and a VL domain that bind to a T cell surface antigen, and
- b) a second binding domain comprising a designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface.
3:
- The non-oncolytic virus according to claim 1, wherein said non-oncolytic virus is an adenovirus.
4:
- The non-oncolytic virus according to claim 1, wherein said bispecific T cell engager is encoded in the genome of the non-oncolytic virus.
5:
- The non-oncolytic virus according to claim 1, wherein said trimerization domain is or is derived from the capsid protein SHP of lambdoid phage 21.
6:
- The non-oncolytic virus according to claim 1, wherein said designed ankyrin repeat domain that binds to a knob of an adenovirus comprises the amino acid sequence of SEQ ID No. 2.
7:
- The non-oncolytic virus according to claim 1, wherein said recombinant adapter molecule comprises from the N- to the C-terminus
- a) said designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface,
- b) said designed ankyrin repeat domain which binds to the knob of the adenovirus, and
- c) said trimerization domain.
1 more element
8:
- The non-oncolytic virus according to claim 2, wherein said first binding domain of said bispecific protein comprises a HCDR1 of SEQ ID No. 3, a HCDR2 of SEQ ID No. 4, a HCDR3 of SEQ ID No. 5, a LCDR1 of SEQ ID No. 6, a LCDR2 of SEQ ID No. 7 and a LCDR3 of SEQ ID No. 8.
9:
- The non-oncolytic virus according to claim 2, wherein said target antigen bound by said second binding domain of said bispecific T cell engager and said target antigen exposed on the cell surface and bound by the designed ankyrin repeat domain of said recombinant adapter molecule are the same target antigen.
10:
- The non-oncolytic virus according to claim 9, wherein said target antigen is HER2 (SEQ ID No. 12).
11:
- The non-oncolytic virus according to claim 2, wherein said target antigen bound by said second binding domain of said bispecific T cell engager and said target antigen exposed on the cell surface and bound by the designed ankyrin repeat domain of said recombinant adapter molecule are different target antigens.
12:
- The non-oncolytic virus according to claim 2, wherein said designed ankyrin repeat domain which binds to a target antigen exposed on the cell surface comprises SEQ ID No. 13.
13:
- A method for treatment of cancer in a patient, said method comprising administering to the patient the non-oncolytic virus of claim 1.
14:
- An eukaryotic cell containing a non-oncolytic virus according to claim 1 and/or expressing a bispecific T cell engager encoded on the genome of said non-oncolytic virus.
15:
- The non-oncolytic virus according to claim 2 wherein said T cell surface antigen is CD3.
16:
- The non-oncolytic virus of claim 3 wherein the adenovirus is of serotype 5 and/or is a gutless or helper-dependent adenovirus.
17:
- The non-oncolytic virus of claim 5 wherein said trimerization domain comprises the amino acid sequence of SEQ ID No. 1.